# Degron Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/degron-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.degrontx.com
- Total disclosed funding: $82M
- Latest round: Series A (May 14, 2026)
- Investors on record: 21

## About

Based in Shanghai, China, and founded in 2021, Shanghai Dregon Biomedical Technology Co., Ltd, doing business as Degron Therapeutics, operates as a developer of targeted protein degradation technology and new drugs. The company's CEO and Co-founder, Lily Zou, who graduated from Beijing University and served as CEO of Fosun Pharma. It reached a multi-target cooperative research and development and exclusive licensing agreement with Takeda Pharmaceutical Company Limited. In December 2025, Degron Therapeutics closed a round of venture funding from new investor ApicHope.

Degron Therapeutics develops molecular glue degrader compound libraries and targeted protein degradation platforms for drug discovery. Its offerings include molecular glue screening services, phenotypic screening, protein profiling, and in vitro and in vivo target discovery and validation technologies supporting oncology, immune and metabolic disease research programs.

he company generates revenue through research collaborations, licensing agreements, and the development of small molecule protein degraders for therapeutic applications, primarily working with pharmaceutical partners on discovery and preclinical development programs.

The company plans to advance multiple molecular glue degrader programs into clinical development, expand its targeted protein degradation pipeline across oncology, immunology, and metabolic diseases.

## Funding rounds

- Series A, May 14, 2026, $40M — GTJA Investment Group, Shijiazhuang Pharma, Fortune Capital, GF Xinde Investment, Casstar Capital, Lapam Capital, ApicHope, Kinghall Ventures, GAGE Capital
- Series A, Dec 31, 2024, $20M — Takeda Ventures, YuanBio Venture, Zhuhai Longmen Capital Management, Hangzhou Heda Industry Fund Investment, Haoyue Capital, FC Capital - China, AIM-HI Accelerator Fund
- Series A, Jun 9, 2022, $22M — Baidu Ventures, DYEE Capital, MED-FINE Capital, Neux Capital
- Seed, Mar 10, 2021 — YuanBio Venture, Co-Win Ventures

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Seed, Series A
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Seed
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- Neux Capital — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series A
- Hangzhou Heda Industry Fund Investment — Series A
- Haoyue Capital (https://capitalatlas.ai/funds/haoyue-capital) — Series A
- FC Capital - China (https://capitalatlas.ai/funds/fc-capital-china) — Series A
- AIM-HI Accelerator Fund — Series A
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series A
- Shijiazhuang Pharma — Series A
- Fortune Capital — Series A
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series A
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- ApicHope — Series A
- Kinghall Ventures — Series A
- GAGE Capital (https://capitalatlas.ai/funds/gage-capital) — Series A